Novartis Therapy Gilenya Reduced the Risk of MS Disability Progression Regardless of Treatment History or Disease …
A new analysis demonstrated that Gilenya⢠reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis , regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology .
Read more on PR Newswire via Yahoo! Finance
